

**67<sup>th</sup> American Society of Hematology Annual Meeting and Exposition**  
**December 6-9, 2025**  
**Orlando, Florida**  
**Abstracts<sup>1</sup>**

**Multiple Hematology Trials ALC7 and AL6**

**Time:** Monday, December 8, 2025  
**Location:** OCCC – West Halls B3-B4  
**Type:** Poster  
**Session:** 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III  
**Abstract #:** **abs25-12342**  
**Abstract:** ***Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.***  
**Authors:** Eric Winer, Megan Othus, Ehab Atallah, Stephanie Tsai, Mitchell Sabloff, Afaf Osman, Annie Im, Sanam Loghavi, Anna Moseley, Brent Wood, Min Fang, Cecilia Yeung, Xueyan Chen, Xiaoyu QU, Lyndsay Harris, Sayak Ghatak, Steven Gore, Geoffrey Uy, Laura Michaelis, Olatoyosi Odenike, Richard Stone, Selina Luger, Sarit Assouline, Harry Erba, Mark Litzow, Curtis Lachowicz, John Reagan, Uma Borate, Mary Lynn Savoie, Brian Jonas, Ntasha Roy, Jerald Radich, Richard Little, Shahanawaz Jiwani  
**Link:** <https://submit.hematology.org/program/presentation/680397>  
**Citation:**

---

**CCTG ALC.4/ EGOG 1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults**

**Time:** Saturday, December 6, 2025: 9:30pm  
**Location:** OCCC – W224CDGH  
**Type:** Oral  
**Session:** 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis  
**Abstract #:** **abs25-7266**  
**Abstract:** ***Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial***  
**Authors:** Xiaoming Zhong, Kathryn Roberts, Lindsey Montefiori, Zhuoxin Sun, Huimei Wei, Petri Polonen, Ti-Cheng Chang, Wenchao Zhang, Shaohua Lei, Evadnie Rampersaud, Yiping Fan, Gang Wu, Ryan Mattison, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke1, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Martin Tallman, Jun Yang, Elisabeth Paietta, Selina Luger, Mark Litzow, Charles Mullighan  
**Link:** <https://submit.hematology.org/program/presentation/672863>  
**Citation:**

---

<sup>1</sup> A searchable directory of abstracts is available using this link ...

[https://submit.hematology.org/program?is\\_sponsored=0&is\\_highlighted=0&is\\_on\\_demand=0&streaming\\_allowed=0&filterbox=false&legendbox=false&timezone=false&pre\\_filter=All&viewType=list&segment=programme&segmentname=&upcoming=0&order=statics\\_at](https://submit.hematology.org/program?is_sponsored=0&is_highlighted=0&is_on_demand=0&streaming_allowed=0&filterbox=false&legendbox=false&timezone=false&pre_filter=All&viewType=list&segment=programme&segmentname=&upcoming=0&order=statics_at).

---

**CCTG ALC.4/ EGOG 1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults**

**Time:** Saturday, December 6, 2025: 5:30-7:30 PM

**Location:** OCCC – West halls B3-B4

**Type:** Poster Abstract Session

**Session:** 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I

**Abstract#:** abs25-9167

**Abstract:** *Impact of therapy delays on outcomes in adults with BCR:ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab*

**Authors:** Bhavana Bhatnagar, Zhuoxin Sun, Ryan Mattison, Elisabeth Paietta, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Selina Luger, Charles Mullighan, Martin Tallman, Mark Litzow

**Link:** <https://submit.hematology.org/program/presentation/676059>

**Citation:**

---

**CCTG LYC.1/ ECOG 1411: Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB -> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV -> R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)**

**Time:** Sunday, December 7, 2025: 6:00-8:00 PM

**Location:** OCCC - West Halls B3-B4

**Type:** Poster

**Session:** 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

**Abstract #:** abs25-7907

**Abstract:** *Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide*

**Authors:** Christine Ryan, Victoria Wang, Mitchell Smith, Brian Till, Samir Parekh, David Yang, Lale Kostakoglu, Nizar Abdel Samad, Opeyemi Jegede, Richard Little, Jonathan Friedberg, John Leonard, Brad Kahl, Peter Martin

**Link:** <https://submit.hematology.org/program/presentation/675645>

**Citation:**

---

**CCTG HDC.1/ SWOG S1826: A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.**

**Time:** Saturday December 6, 2025: 4:30-4:45PM

**Location:** OCCC – Tangerine Ballroom 1

**Type:** Oral

**Session:** 621. Lymphomas: Translational – Molecular and Genetic: Towards Precision Medicine in Lymphoma: Multi-Omics Discovery of Prognostic and Predictive Biomarkers

**Abstract #:** abs25-8300

**Abstract:** *Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826*

**Authors:** Julia Paczkowska, Marcin Kaszkowiak, Michael Leblanc, Chip Stewart, Alex Herrera, Juan Carlos Fernandez del Castillo, Sharon Castellino, Sarah Rutherford, Andrew Evens, Kelly Davison, Hongli Li, Donna Neuberg, Mark Murakami, Jasmine Makker, Brad Kahl, John Leonard, Nancy Bartlett, Sonali Smith, Joo Song, Kara Kelly, Gad Getz, Jonathan Friedberg, Margaret Shipp

**Link:** <https://submit.hematology.org/program/presentation/678023>

**Citation:**

---

**CCTG HDC.1/ SWOG S1826: A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.**

**Type:** Poster

**Session:** 621. Lymphomas: Translational – Molecular and Genetic: Towards Precision Medicine in Lymphoma: Multi-Omics Discovery of Prognostic and Predictive Biomarkers

**Abstract #:** abs25-12591

**Abstract:** *Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study*

**Authors:** Nancy Bartlett, Hongli Li, Michael Knopp, Chad Wright, Heiko Schoder, Lawrence Schwartz, Sharon Castellino, Sarah Rutherford, Andrew Evens, Kelly Davison, Angela Punnett, Margaret Shipp, Brad Kahl, John Leonard, Sonali Smith, Joo Song, Lale Kostakoglu, Kara Kelly, Michael LeBlanc, Jonathan Friedberg, Alex Herrera

**Citation:** <https://doi.org/10.1182/blood-2025-1851>

---